These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 30127305)

  • 1. The Emerging Role of Pathogenesis of IgA Nephropathy.
    Wu MY; Chen CS; Yiang GT; Cheng PW; Chen YL; Chiu HC; Liu KH; Lee WC; Li CJ
    J Clin Med; 2018 Aug; 7(8):. PubMed ID: 30127305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis.
    Suzuki H; Yasutake J; Makita Y; Tanbo Y; Yamasaki K; Sofue T; Kano T; Suzuki Y
    Kidney Int; 2018 Mar; 93(3):700-705. PubMed ID: 29329643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers for IgA nephropathy on the basis of multi-hit pathogenesis.
    Suzuki H
    Clin Exp Nephrol; 2019 Jan; 23(1):26-31. PubMed ID: 29740706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.
    Suzuki Y; Suzuki H; Yasutake J; Tomino Y
    Expert Opin Biol Ther; 2015 Apr; 15(4):583-93. PubMed ID: 25604055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of aberrantly expressed profiles of mRNA and its relationship with serum galactose-deficient IgA1 level in IgA nephropathy.
    Liu Y; Liu X; Jia J; Zheng J; Yan T
    J Transl Med; 2019 Sep; 17(1):320. PubMed ID: 31547815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Significance of Galactose-Deficient IgA1 by KM55 in Patients with IgA Nephropathy.
    Zhang K; Li Q; Zhang Y; Shang W; Wei L; Li H; Gao S; Yan T; Jia J; Liu Y; Lin S
    Kidney Blood Press Res; 2019; 44(5):1196-1206. PubMed ID: 31574506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural features of IgA molecules which contribute to IgA nephropathy.
    Feehally J; Allen AC
    J Nephrol; 1999; 12(2):59-65. PubMed ID: 10378660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy.
    Sugiyama M; Wada Y; Kanazawa N; Tachibana S; Suzuki T; Matsumoto K; Iyoda M; Honda H; Shibata T
    PLoS One; 2020; 15(4):e0232194. PubMed ID: 32324811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation in IgA nephropathy.
    Rauen T; Floege J
    Pediatr Nephrol; 2017 Dec; 32(12):2215-2224. PubMed ID: 28293726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IgA nephropathy: an update.
    Julian BA; Novak J
    Curr Opin Nephrol Hypertens; 2004 Mar; 13(2):171-9. PubMed ID: 15202611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future?].
    Segarra A
    Nefrologia; 2010; 30(5):501-7. PubMed ID: 20882091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and targeted new therapies for IgA nephropathy.
    Coppo R
    Pediatr Nephrol; 2017 May; 32(5):725-731. PubMed ID: 27324471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
    Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
    BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic Mutations Modulate Autoantibodies against Galactose-Deficient IgA1 in IgA Nephropathy.
    Huang ZQ; Raska M; Stewart TJ; Reily C; King RG; Crossman DK; Crowley MR; Hargett A; Zhang Z; Suzuki H; Hall S; Wyatt RJ; Julian BA; Renfrow MB; Gharavi AG; Novak J
    J Am Soc Nephrol; 2016 Nov; 27(11):3278-3284. PubMed ID: 26966014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
    Suzuki H; Moldoveanu Z; Hall S; Brown R; Julian BA; Wyatt RJ; Tomana M; Tomino Y; Novak J; Mestecky J
    Contrib Nephrol; 2007; 157():129-33. PubMed ID: 17495450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum galactose-deficient IgA1 levels in children with IgA nephropathy.
    Jiang M; Jiang X; Rong L; Xu Y; Chen L; Qiu Z; Mo Y
    Int J Clin Exp Med; 2015; 8(5):7861-6. PubMed ID: 26221341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
    Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
    Front Immunol; 2019; 10():504. PubMed ID: 30941137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Murine Models of Human IgA Nephropathy.
    Suzuki H; Suzuki Y
    Semin Nephrol; 2018 Sep; 38(5):513-520. PubMed ID: 30177023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.
    Novak J; Moldoveanu Z; Renfrow MB; Yanagihara T; Suzuki H; Raska M; Hall S; Brown R; Huang WQ; Goepfert A; Kilian M; Poulsen K; Tomana M; Wyatt RJ; Julian BA; Mestecky J
    Contrib Nephrol; 2007; 157():134-8. PubMed ID: 17495451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Understanding of the Role of Complement in IgA Nephropathy.
    Maillard N; Wyatt RJ; Julian BA; Kiryluk K; Gharavi A; Fremeaux-Bacchi V; Novak J
    J Am Soc Nephrol; 2015 Jul; 26(7):1503-12. PubMed ID: 25694468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.